GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use
- 21 April 2023
- journal article
- review article
- Published by Springer Nature in Current Obesity Reports
- Vol. 12 (2) , 61-74
Abstract
Purpose of Review To discuss current literature and provide practical recommendations for the safe and effective use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) in people with inflammatory bowel disease (IBD) and type 2 diabetes (T2D) and/or obesity. The molecular mechanisms that justify the potential benefits of GLP-1 RA in IBD and the links between IBD, obesity, and cardiovascular disease are also discussed. Recent Findings Preliminary data suggest that GLP-1 RA can modulate crucial pathways in the pathogenesis of IBD, such as chronic inflammation circuits, intestinal tight junctions, and gut microbiome dysbiosis, setting the stage for human trials to investigate the role of these agents in the treatment of IBD among people with or without diabetes and obesity. However, gastrointestinal side effects related to GLP-1 RA need appropriate clinical management to mitigate risks and maximize the benefits of therapy in people with IBD. Summary GLP-1 RA originally emerged as drugs for the treatment of hyperglycemia and are currently licensed for the management of T2D and/or overweight/obesity. However, their wealth of pleiotropic actions soon raised expectations that they might confer benefits on non-metabolic disorders. Future studies are expected to clarify whether GLP-1 RA deserve an adjunct place in the arsenal of drugs against IBD.Keywords
This publication has 114 references indexed in Scilit:
- A clinical review of recent findings in the epidemiology of inflammatory bowel diseaseClinical Epidemiology, 2013
- Liver Disorders in Inflammatory Bowel DiseaseGastroenterology Research and Practice, 2012
- The combination of high-fat diet-induced obesity and chronic ulcerative colitis reciprocally exacerbates adipose tissue and colon inflammationLipids in Health and Disease, 2011
- Increase in Plasma Endotoxin Concentrations and the Expression of Toll-Like Receptors and Suppressor of Cytokine Signaling-3 in Mononuclear Cells After a High-Fat, High-Carbohydrate MealDiabetes Care, 2009
- Interleukin-10-independent anti-inflammatory actions of glucagon-like peptide 2American Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- The Role of Incretins in Glucose Homeostasis and Diabetes TreatmentPharmacological Reviews, 2008
- Glucose and GLP-1 Stimulate cAMP Production via Distinct Adenylyl Cyclases in INS-1E Insulinoma CellsJournal of General Physiology, 2008
- The intestinal epithelium: sensors to effectors in nematode infectionMucosal Immunology, 2008
- The Montreal classification of inflammatory bowel disease: controversies, consensus, and implicationsGut, 2006
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005